AzTrials
AzTrials

Cardiovascular (CV) RiskCARDIOMOMNCT07356817

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

An observational study of Cardiovascular (CV) Risk and Preeclampsia (PE), run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women… Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
How many people
1,260 participants
Where
1 siteSpain
Study dates
28 Aug 2023to 31 Dec 2026
How long will I take part?
1 Day
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Young women who presented an index pregnancy with and without placental complications, who have previously participated in cohort studies performed by our group identifying biophysical, biochemical, psychosocial and environmental cardiovascular risk factors during pregnancy

Who may be able to join

  • Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1/PlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16/00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19/00702) cohort studies
  • Who have delivered within the previous 3-6 years.
  • Give written consent when invited to participate in this study protocol.

Who cannot join

  • Unwillingness to participate in this study
  • Probability of loss to follow-up.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Elisa Llurba Olivé, PhD contact

+34 935534078

ellurba@santpau.cat

Pablo García Manau, PhD contact

+34 627813346

pgarciama@santpau.cat

Spain1 site, 1 recruiting
  • Hospital de la Santa Creu i de Sant Pau

    Barcelona, 08025

    Pablo García Manau, PhD, +34 627813346, pgarciama@santpau.cat

    Recruiting

Other trials in Spain

About this study

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.

The goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.

Read the detailed description

Cardiovascular diseases (CVD) are the leading cause of death among women, particularly non-obstructive myocardial infarction, heart failure, and stroke. However, neither women themselves nor, often, their physicians are fully aware of this reality. This lack of awareness is partly due to gender-related myths and biases that have led to insufficient study of the specific causes and risk factors that affect women's cardiovascular systems. Traditionally, it has been assumed that cardiovascular risk mechanisms, prediction, diagnosis, and treatment are the same in men and women. Today, it is known that this is not true: while the severity and mortality due to cardiovascular disease have decreased in men, they continue to rise and remain more severe among women.

Reproductive history and hormonal influence play a decisive role in modulating cardiovascular risk in women. Experiencing complications during pregnancy - such as preeclampsia (a hypertensive disorder caused by abnormal placental function), preterm delivery, or the birth of a low-weight infant - increases the risk of cardiovascular complications up to sevenfold later in life, compared with women who had normal pregnancies. This is explained by the fact that the cardiovascular system undergoes major adaptive changes during pregnancy; in complicated pregnancies, these adaptations fail to occur properly, resulting in cardiovascular stress and damage.

Among the objectives of this project, the investigators also aim to evaluate other risk factors such as lifestyle and external influences like exposure to environmental pollutants, which may further contribute to cardiovascular vulnerability. Pregnancy represents a critical window of susceptibility - as seen in other conditions such as COVID-19 - during which these environmental and biological impacts on the cardiovascular system are amplified.

In this project, the aim is to investigate how all these factors determine cardiovascular health in a cohort of 1,800 mothers, assessed 3 to 6 years after childbirth. The investigators will also examine how postnatal lifestyle and self-care behaviors may either mitigate or exacerbate this imprint. Women often prioritize their families' needs over their own, which can make it difficult to maintain healthy habits that reduce cardiovascular risk. Moreover, the investigators will study how environmental exposures influence maternal health and explore potential predictive and preventive strategies.

The goal is to develop an easy-to-use algorithm or test - ideally in the form of a mobile application - to help women and their physicians assess cardiovascular risk. Although predictive algorithms for cardiovascular health already exist, they have mostly been developed in predominantly male or older populations, and none have considered pregnancy-related factors or environmental exposures, both of which are key determinants of women's cardiovascular health.

To date, preventive cardiovascular strategies have not been specifically designed for women, and even less so for recently postpartum women. Existing tools have not been adapted for this population. This project brings together obstetricians and cardiologists, as well as midwives and primary care physicians - the healthcare professionals primarily responsible for women's health and well-being. The investigators believe that this multidisciplinary approach is crucial to anticipate cardiovascular disease and implement truly preventive strategies.

All study findings will be disseminated through educational sessions for healthcare professionals, new clinical tools and practices to improve patient satisfaction, audiovisual materials for better maternal health communication, and through professional societies (such as SEGO, SEC, SEAP, SEM, etc.). Results will also be published in open-access scientific journals and shared via public outreach, including media coverage, conferences in hospitals and community centers, social media (@DonaSantPau), and the institutional website (http://www.santpau.cat/web/public/go-inici

).

The active participation of women in this study will also allow the creation of discussion and advocacy groups among participants, supporting dissemination through social media, online platforms (https://inatal.org), and patient associations (such as El parto es nuestro), as well as newspapers, radio, and television.

Keywords
preeclampsia, Cardiovascular Risk, app
Medical subject headings
Pre-Eclampsia, Fetal Weight, Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07356817
Study groupRoleWhat they receive
Young women with an index pregnancy with and without placental complicationsCV biophysical, imaging and biochemical variables 3-6 years after index pregnancy (approximate n=1260) will be evaluated. Analyses will include urbanome, placental function and perinatal variables during index pregnancy and postnatal variables such as maternal socio-economic status, lifestyle, urban exposome, mental health, blood pressure, cardiac function, coronary artery disease by Coronary Computed Tomography (CCT) and CCT angiography, RM Quantitative Myocardial Perfusion, ophthalmic artery index, carotid intima- media thickness up to 6 years after delivery to predict higher risk for CVD later in life. Patients' needs and expectations according to CV health would be evaluated.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hypertension

    Presence of hypertension, defined as stage 1 hypertension (SBP of 130-139 or DBP of 80-89 mmHg)

    Measured: 3-6 years after index pregnancy

  2. Abnormal cardiac function

    Abnormal cardiac function in the echocardiographic ultrasound assessment. Abnormal values of the different parameters will be considered according to reference limits published in 2020 by the British Society of Echocardiography

    Measured: 3-6 years after index pregnancy

  3. Biochemical cardiac markers

    Abnormal biochemical cardiac markers: NTproBNP >300 ng/L or high-sensitivity troponin>30 ng/L

    Measured: 3-6 years after index pregnancy

  4. Coronary artery disease

    Signs of coronary artery disease by computer tomography (CCT) myocardial perfusion imaging (mild (CACS≥10 AU and <100 AU); moderate (CACS≥100 AU and <400 AU) and severe (CACS ≥400 AU)

    Measured: 3-6 years after index pregnancy

  5. Other cardiovascular major events

    Cardiovascular major events (ictus, coronary artery disease, cardiac insufficiency or myocardiopathy)

    Measured: 3-6 years after index pregnancy

Secondary outcomes (45)
  1. Age

    Patient age

    Measured: 3-6 years after index pregnancy

  2. Pregnancy complications

    Preeclampsia, pregnancy complications, presence of fetal distress, perinatal mortality, neonatal morbidity, and neonatal mortality.

    Measured: 3-6 years after index pregnancy

  3. Antrophometric measurements

    Percentages of body fat, muscle mass, visceral fat

    Measured: 3-6 years after index pregnancy

  4. Blood pressure

    Systolic and Dyastolic blood pressure

    Measured: 3-6 years after index pregnancy

  5. Computer tomography (CCT) myocardial perfusion imaging and RM Quantitative Myocardial Perfusion

    Allows an accurate and reliable assessment of both coronary epicardial stenosis and myocardial CT perfusion imaging at rest and during pharmacologic stress in the same examination. CCT will be performed with a 256-slice CT scanner (Philips Healthcare scanner) with prospective ECG-triggering as previously described. First, a noncontrast CCT will be performed to calculate the CACS using the Agatston scoring method. Second, CCTA will be performed following sublingual nitroglycerin and injection of nonionic contrast (Iopromide, Ultravist, Bayer Healthcare, Berlin, Germany). The presence of any coronary plaque (noncalcified, calcified, or mixed) and the presence of significant stenosis (≥50%) was assessed in all 17 coronary segments. One of 2 assigned and experienced cardiovascular radiologists assessed the CT scans for each participant.

    Measured: 3-6 years after index pregnancy

  6. Cardiovascular markers in maternal blood

    Venous blood samples will be collected without anticoagulant to obtain serum. Troponin T and NTproBNP will be measured in ng/ml using automated electrochemiluminescence immunoassays on the Roche Cobas platform (Roche Diagnostics GmbH, Mannheim, Germany).Intra-and interassay coefficients of variation were found to be <5%.

    Measured: 3-6 years after index pregnancy

  7. Laboratory data measured in mg/dl

    glucose, uric acid, creatinine, VLDL, LDL, HDL, total cholesterol, triglycerides

    Measured: 3-6 years after index pregnancy

  8. Cardiovascular assessment according to IBERLIFERISK score

    A score >50% is considered as a high-risk for CVD.

    Measured: 3-6 years after index pregnancy

  9. Hair sampling for cortisol determination

    Hair samples will be cut with scissors from the region of the posterior vertex, as close to the scalp as possible. Considering that hair grows approximately 1 cm per month, 3 cm will be obtained in order to evaluate hair cortisol levels representative of the last 3 months. Samples will be stored (in a dark container at room temperature) until analysis by liquid chromatography mass spectrometry.

    Measured: 3-6 years after index pregnancy

  10. Diet and nutrition

    evaluated by means of the Short Diet Quality Screener by REGICOR (registre Gironí del Cor) and by means of the validated 14-item questionnaire of adherence to the Mediterranean diet. Escale from 1-31. The highest the score, the highest the adherence to the mediterranean diet.

    Measured: 3-6 years after index pregnancy

  11. Physical activity

    evaluated by means of the Physical Activity Questionnaire by REGICOR, a validated questionnaire for quantifying physical activity in our population. The short questionnaire estimates energy expenditure in total PA and by intensity (light, moderate, vigorous), and includes 2 questions about sedentary behavior and a question about occupational PA.

    Measured: 3-6 years after index pregnancy

  12. Stress

    evaluated by the Perceived Stress Scale (PSS) Questionnaire, validated for quantifying perceived stress in our population. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived this: Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress.

    Measured: 3-6 years after index pregnancy

  13. Mental health

    evaluated by the Psychiatric Diagnostic Screening Questionnaire (PDSQ), a brief, psychometrically strong, self-report scale designed to screen for the most common disorders encountered in outpatient mental health settings and validated in our population. The final version of the questionnaire contains 13 subscales (major depressive disorder [MDD], bulimia, post-traumatic stress disorder [PTSD], panic disorder, agoraphobia, social phobia, generalized anxiety disorder [GAD], obsessive-compulsive disorder [OCD], alcohol abuse/dependence, drug abuse/dependence, somatization, hypochondriasis, and psychosis). Additionally, there is a six-item psychosis screen.

    Measured: 3-6 years after index pregnancy

  14. Smoking habit

    evaluated by the Fagerström Questionnaire, validated questionnaire for quantifying dependence on smoking in our population.

    Measured: 3-6 years after index pregnancy

  15. Women experiences and eHealth

    For this aim, a team of anthropologists with a long experience in the fields of health and reproduction will use qualitative methods to understand the needs of women with and without CV risk after pregnancy. To this end, semistructured interviews will be undertaken with patients with low and high risk of CV disease. These interviews will be useful to have a deep understanding of the difficulties, desires, and needs in relation to interactions with practitioners and available services in healthcare settings. For proactive monitoring and follow-up of patients, a technological platform or App (CardioPlan), currently used for cardiac rehabilitation, will be restructured, which has a highly secure data repository located on the provider's server and then validated in a subgroup of patients (n=100).

    Measured: 3-6 years after index pregnancy

  16. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: 3-6 years after index pregnancy

  17. Waist/Hip ratio

    Measurements in cm2 of waist and hip to calculate waist/hip ratio in cm2

    Measured: 3-6 years after index pregnancy

  18. Heart rate

    Measured in hpm

    Measured: 3-6 years after index pregnancy

  19. Echocardiographic assesment

    Performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High-resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis.

    Measured: 3-6 years after index pregnancy

  20. Myocardial deformation (strain)

    measured by echocardiography is increasingly recognized as a more effective technique than conventional ejection fraction (EF) in detecting subtle changes in left ventricular (LV) function and in predicting outcomes. AutoStrain TOMTEC Philips EPIQ CVx ultrasound systemwould be used for the analysis.

    Measured: 3-6 years after index pregnancy

  21. Carotid intima-media thickness

    Transverse longitudinal evaluation of the common carotid artery, its bifurcation and internal carotid artery. Thickness of the intima layer is measured at the middle third of the common carotid artery and is considered the measurement between the tunica intima and tunica media, the innermost two layers of the wall of an artery.

    Measured: 3-6 years after index pregnancy

  22. ophthalmic artery evaluation

    The woman is placed in a supine position to rest for 5 minutes. A 7.5-MHz linear transducer is then placed transversely and gently over her closed upper eyelid after application of conduction gel. Color flow Doppler is used to identify the ophthalmic artery, which is found superior and medially to the hypoechoic band representing the optic nerve. Pulsed-wave Doppler is then used to record 3 to 5 similar waveforms. Doppler studies are performed twice in each eye, and the average of the 4 measurements is used for analysis.

    Measured: 3-6 years after index pregnancy

  23. Cardiovascular markers in maternal blood

    Venous blood samples will be collected without anticoagulant to obtain serum. Placental growth factor (PlGF) will be measured in pg/ml using automated electrochemiluminescence immunoassays on the Roche Cobas platform (Roche Diagnostics GmbH, Mannheim, Germany).Intra-and interassay coefficients of variation were found to be <5%.

    Measured: 3-6 years after index pregnancy

  24. Laboratory data measured in g/l

    Venous blood samples and urine samples will be collected to measure hemoglobin and protein in urine

    Measured: 3-6 years after index pregnancy

  25. Laboratory data measured in l/l

    Venous blood samples will be collected to measure hematocrit

    Measured: 3-6 years after index pregnancy

  26. Laboratory data measured in U/mcl

    Venous blood samples will be collected to measure leukocytes and platalets

    Measured: 3-6 years after index pregnancy

  27. Laboratory data measured in mmol/l

    Venous blood samples will be collected to measure potassium and sodium

    Measured: 3-6 years after index pregnancy

  28. Laboratory data measured in %

    Venous blood samples will be collected to measure glicated hemoglobin

    Measured: 3-6 years after index pregnancy

  29. Laboratory data measured in U/L

    Venous blood samples will be collected to measure alanine transaminases, aspartate aminotransferases and lactate dehydrogenase

    Measured: 3-6 years after index pregnancy

  30. Laboratory data measured in mg/l

    Urine samples will be collected to measure albumin

    Measured: 3-6 years after index pregnancy

  31. Laboratory data measured in mUI/l

    Venous blood samples will be collected to measure tirotropin and prolactin

    Measured: 3-6 years after index pregnancy

  32. Ethnicity

    Patient ethnicity

    Measured: 3-6 years after index pregnancy

  33. Smoking status

    Patient smoking status

    Measured: 3-6 years after index pregnancy

  34. Menstrual type

    Patient menstrual type and presence of menopause

    Measured: 3-6 years after index pregnancy

  35. Diseases

    Diabetes, obesity, and other maternal diseases associated with cardiovascular risk

    Measured: 3-6 years after index pregnancy

  36. Interval from index preganancy

    interval in years from index pregnancy.

    Measured: 3-6 years after index pregnancy

  37. Gestational age at delivery

    Gestational age at delivery in index pregnancy

    Measured: 3-6 years after index pregnancy

  38. Mode of delivery

    mode of delivery at index pregnancy,

    Measured: 3-6 years after index pregnancy

  39. Labor induction

    labor induction at index pregnancy

    Measured: 3-6 years after index pregnancy

  40. Child's gender

    Child's gender in index pregnancy

    Measured: 3-6 years after index pregnancy

  41. Birth weight percentile

    birth weight percentile in index pregnancy

    Measured: 3-6 years after index pregnancy

  42. Birth weight

    Child's birth weight at index pregancy.

    Measured: 3-6 years after index pregnancy

  43. APGAR score

    5-minute Apgar score in index pregnancy. Apgar score measures appareance, pulse, grimance, acivity and respiratory effort. For each chriteria newborns can receive a punctuation from 0 to 2, qhere 2 is the better punctuation.

    Measured: 3-6 years after index pregnancy

  44. Blood preassure during pregnancy

    Blood preassure druing index pregnancy

    Measured: 3-6 years after index pregnancy

  45. Weight during pregnancy

    Weight during index pregnancy.

    Measured: 3-6 years after index pregnancy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2026
  2. Study start28 Aug 2023
  3. Primary completion30 Sep 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,260 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07356817
Sponsor's protocol ID
IIBSP-MOM-2022-87
Acronym
CARDIOMOM
Status last verified
Nov 2025
First submitted
14 Nov 2025
Last updated
21 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Brotons C, Moral I, Fernandez D, Puig M, Calvo Bonacho E, Martinez Munoz P, Catalina Romero C, Quevedo Aguado LJ. Estimation of Lifetime Risk of Cardiovascular Disease (IBERLIFERISK): A New Tool for Cardiovascular Disease Prevention in Primary Care. Rev Esp Cardiol (Engl Ed). 2019 Jul;72(7):562-568. doi: 10.1016/j.rec.2018.05.028. Epub 2018 Aug 7. English, Spanish.

    PubMed 30097396
  • Ferencik M, Pencina KM, Liu T, Ghemigian K, Baltrusaitis K, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, Hoffmann U. Coronary Artery Calcium Distribution Is an Independent Predictor of Incident Major Coronary Heart Disease Events: Results From the Framingham Heart Study. Circ Cardiovasc Imaging. 2017 Oct;10(10):e006592. doi: 10.1161/CIRCIMAGING.117.006592.

    PubMed 28956774
  • Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy B, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta. 2011 Apr 11;412(9-10):748-54. doi: 10.1016/j.cca.2010.12.034. Epub 2011 Jan 8.

    PubMed 21219893
  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb;27(3):330-7. doi: 10.1093/eurheartj/ehi631. Epub 2005 Nov 17.

    PubMed 16293638
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13. No abstract available.

    PubMed 29146535

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiovascular (CV) Risk and Preeclampsia (PE), run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Elisa Llurba Olivé, PhD (+34 935534078, ellurba@santpau.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hypertension (time frame: 3-6 years after index pregnancy). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07356817, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in